BWX Technologies, Inc. annual report, FY2023

BWX Technologies, Inc. 2023 Form 10-K Summary

Business context and reporting period

BWXT filed its Form 10-K for the fiscal year ended December 31, 2023. The company operates two reportable segments: Government Operations, which supplies naval nuclear components, fuel, uranium processing, government site services and advanced nuclear technologies; and Commercial Operations, which supplies commercial nuclear equipment, services, fuel, medical radioisotopes and radiopharmaceutical products.

The U.S. Government accounted for approximately 75% of consolidated revenue, and large utility customers represented approximately 14%. BWXT employed approximately 7,800 people at year-end.

Financial performance and key metrics

Metric	2023	2022	Change
Revenue	$2.496 billion	$2.233 billion	+11.8%
Operating income	$383.1 million	$348.6 million	+9.9%
Operating margin	15.3%	15.6%	Down approximately 30 bps
Net income attributable to BWXT	$245.8 million	$238.2 million	+3.2%
Diluted EPS	$2.68	$2.60	+3.1%
Net cash from operations	$363.7 million	$244.7 million	+$119.0 million
Capital expenditures	$151.3 million	$198.3 million	Down $47.0 million

Government Operations revenue increased 12.3% to $2.031 billion, while operating income increased 11.4% to $374.7 million. Segment margin was 18.4%, compared with 18.6% in 2022.
Commercial Operations revenue increased 9.1% to $466.3 million, while operating income increased 36.9% to $37.5 million. Segment margin improved to 8.0% from 6.4%.
Income before tax was $321.4 million, and the effective tax rate was 23.4%, compared with 24.1% in 2022.
Cash and cash equivalents were $75.8 million at year-end; total cash, including restricted cash, was $81.6 million. Management reported total liquidity of approximately $649.1 million, including unrestricted cash and available credit capacity.
Working capital increased to $442.8 million from $403.8 million.
Total debt principal was approximately $1.213 billion, consisting of $800 million of senior notes and $418.8 million outstanding under the credit facility. Net long-term debt reported on the balance sheet was $1.203 billion after deferred issuance costs.
The company paid approximately $85.0 million in common-stock dividends during 2023 and ended the year with $397.6 million remaining under its share-repurchase authorization.
Backlog was approximately $3.998 billion at December 31, 2023, including $414.7 million of unfunded U.S. Government backlog. Management expected approximately 51% of backlog revenue to be recognized by the end of 2024.

Material changes versus the prior comparable period

Revenue growth was driven primarily by higher volume in nuclear component manufacturing, increased advanced-technology design and engineering work, and higher uranium processing and downblending activity.
Commercial revenue benefited from increased in-plant inspection, maintenance, modification and refurbishment services and higher medical radioisotope revenue.
Operating income benefited from favorable contract estimate and change-order adjustments totaling $50.4 million in Government Operations, including $22.5 million related to a nuclear operations contract and $27.9 million from negotiated change orders.
Other expense worsened to $61.7 million from $34.2 million, primarily because pension and postretirement mark-to-market results shifted to a $20.9 million loss from a $4.0 million gain and interest expense increased by $10.6 million.
Corporate expenses increased to $29.2 million from $15.3 million, largely due to higher healthcare and compensation costs and information-technology transformation spending.
Net cash from operations improved substantially, while investing cash outflows declined due to lower capital spending and the absence of the prior-year $46.7 million acquisition of Dynamic Controls and Cunico.
Net debt borrowings declined, resulting in $169.4 million of financing cash outflows compared with $14.0 million of financing cash inflows in 2022.
Quarterly fourth-quarter revenue was $725.5 million, operating income was $123.2 million and net income attributable to BWXT was $65.9 million. Fourth-quarter results included a $27.9 million favorable contract adjustment and a $30.8 million pretax unfavorable pension and postretirement adjustment.

Guidance, outlook, risks and unusual items

Management did not provide a specific full-year 2024 revenue or earnings forecast in the filing. The stated outlook is supported by the backlog, expected 2024 conversion of approximately 51% of backlog, continued U.S. Navy and national-security demand, advanced-reactor development and Canadian nuclear refurbishment activity. Management expects elevated capital spending associated with major expansion projects to decline as those projects are substantially completed.

Government Operations remains highly dependent on U.S. Government appropriations, contract renewals, option exercises and customer performance evaluations. Government shutdowns, continuing resolutions, budget reductions or contract termination could delay revenue and cash flows.
Approximately 93% of Government Operations revenue came from the U.S. Government, and approximately 77% of Commercial Operations revenue came from large utility customers, creating customer and program concentration.
Long-term contracts are generally recognized over time using cost-to-cost estimates. Changes in labor productivity, material prices, project scope, schedule or contract estimates could materially change future revenue and profit.
Fixed-price contracts expose BWXT to cost overruns, supplier delays, liquidated damages and execution risk. Backlog may be cancelled, modified or delayed and is not necessarily indicative of future earnings.
Environmental accruals, including asset retirement obligations, totaled $101.1 million at year-end. Future remediation, decommissioning and regulatory requirements could exceed recorded amounts.
The company had $114.6 million of surety bonds and $38.4 million of letters of credit outstanding. Regulatory and contractual bonding and letter-of-credit capacity may become more costly or unavailable.
Defined benefit plans were underfunded by approximately $75.4 million for pension benefits; pension and postretirement accounting can create significant earnings volatility.
The Price-Anderson Act’s statutory authority was scheduled to expire December 31, 2025. Existing contract and license protections generally remain in place, but failure to extend the authority could affect future work and licenses.
Management stated that cybersecurity incidents had not materially affected the company through the filing date, but identified cybersecurity, classified information, operational technology and CMMC compliance as continuing risks.
Deloitte & Touche issued unqualified opinions on the financial statements and internal control over financial reporting. Revenue recognition and estimation of costs to complete long-term contracts was identified as the critical audit matter.

Most important facts for an investor to verify

Whether U.S. Government appropriations, contract awards and option exercises support conversion of the $3.998 billion backlog, particularly the $414.7 million unfunded portion.
Whether the favorable 2023 contract adjustments are nonrecurring and whether future contract estimates remain accurate without similar benefits.
Progress, margins and cash requirements for Canadian nuclear refurbishment projects and the medical radioisotope business.
Debt refinancing and repayment capacity, including the $387.5 million of scheduled 2027 credit-facility maturities and $400 million senior notes due in both 2028 and 2029.
Changes in pension assumptions, funding requirements and mark-to-market gains or losses.
Environmental, decommissioning, nuclear-liability and litigation exposures relative to recorded accruals and available indemnification or insurance.
Whether operating cash flow remains strong after normalized working-capital movements, capital expenditures, dividends and potential acquisitions.